{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:34:34Z","timestamp":1789796074358,"version":"4.0.1"},"reference-count":33,"publisher":"American Society for Clinical Investigation","issue":"13","funder":[{"name":"Vaxart, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,12]]},"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND.<\/jats:bold>\n                    Noroviruses are the leading cause of epidemic acute gastroenteritis and foodborne diarrheal disease in humans. However, there are no approved vaccines for noroviruses. Potential correlates of protection identified through human challenge studies include mucosal IgA, memory B cells, and serum-blocking antibody titers (BT50).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>METHODS.<\/jats:bold>\n                    We conducted a single-site, randomized, double-blind, placebo-controlled clinical trial of an oral norovirus vaccine to determine safety and immunogenicity. This tablet vaccine is comprised of a nonreplicating adenovirus-based vector expressing the\n                    <jats:italic>VP1<\/jats:italic>\n                    gene from the GI.1 norovirus strain and a double-stranded RNA adjuvant. Sixty-six adult subjects meeting inclusion\/exclusion criteria were randomized 2:1 to receive a single vaccine dose or placebo, respectively. Immunogenicity was primarily assessed by serum BT50. Additional outcomes included serum ELISA titers, fecal and saliva antibody titers, memory and antibody-secreting cell (ASC) frequency, and B cell phenotyping.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS.<\/jats:bold>\n                    The vaccine was well-tolerated, with no dose-limiting toxicities. Adverse events were mild or moderate. The primary immunological endpoint (increase in BT50 titers) was met in the high-dose group (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.0003), with 78% showing a \u22652-fold rise in titers after a single immunization. Vaccine recipients also developed mucosally primed VP1-specific circulating ASCs, IgA\n                    <jats:sup>+<\/jats:sup>\n                    memory B cells expressing gut-homing receptor (\u03b14\u03b27), and fecal IgA, indicating substantial and local responses potentially relevant to prevent norovirus infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION.<\/jats:bold>\n                    This oral norovirus vaccine was well-tolerated and generated substantial immune responses, including systemic and mucosal antibodies as well as memory IgA\/IgG. These results are a major step forward for the development of a safe and immunogenic oral norovirus vaccine.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>TRIAL REGISTRATION.<\/jats:bold>\n                    ClinicalTrials.gov NCT02868073.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>FUNDING.<\/jats:bold>\n                    Vaxart.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.121077","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T11:01:22Z","timestamp":1531306882000},"source":"Crossref","is-referenced-by-count":120,"title":["Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial"],"prefix":"10.1172","volume":"3","author":[{"given":"Leesun","family":"Kim","sequence":"first","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liebowitz","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lin","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6550-200X","authenticated-orcid":true,"given":"Kassandra","family":"Kasparek","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-1342","authenticated-orcid":true,"given":"Shaily J.","family":"Garg","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Trager","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean N.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Vaxart, South San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1086\/342386"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu120"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804575"},{"issue":"5 Suppl 1","key":"B4","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ajic.2010.04.196","article-title":"Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, Clostridium difficile, and Acinetobacter species","volume":"38","author":"Weber","year":"2010","journal-title":"Am J Infect Control"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004134"},{"issue":"8","key":"B6","first-page":"20","article-title":"Outbreak of norovirus illness in a college summer camp: impact of cleaning on occurrence of norovirus on fomites","volume":"76","author":"Fankem","year":"2014","journal-title":"J Environ Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12560-014-9145-5"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.077"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1101245"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu497"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.1.18"},{"issue":"2","key":"B12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CDLI.5.2.247-250.1998","article-title":"Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine","volume":"5","author":"Kilhamn","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1086\/656364"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm860"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005334"},{"key":"B16","article-title":"Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00266-2"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146010"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.02.009"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2003.12.015"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/331041a0"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.12.008"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2007.6"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2007.14"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151219"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01229.x"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00552-12"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1086\/657087"},{"issue":"5","key":"B29","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00571-16","article-title":"B-cell responses to intramuscular administration of a bivalent virus-like particle human norovirus vaccine","volume":"24","author":"Ramani","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6616(03)00120-7"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/08820131003622635"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.41"},{"key":"B33","unstructured":"Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. FDA. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/ucm091977 Accessed June 15, 2018"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/121077\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:59:33Z","timestamp":1779195573000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/121077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":33,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2018,7,12]]},"published-print":{"date-parts":[[2018,7,12]]}},"alternative-id":["10.1172\/jci.insight.121077"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.121077","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"article-number":"e121077"}}